CD274 and osteosarcoma: In a clinical trial, 60 patients with osteosarcoma presenting with metastases received TIL infusion combined with anti-PD-L1 therapy, and only 2 (3.33%) patients experienced grade 3 or 4 treatment-related adverse effects.